Tertiary amide derivatives substituted with 4-membered ring structure
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition. [Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1): wherein A represents CHF, or CH 2 , B represents the following Formula (B-1): Ring Q represents an optionally substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally substituted 5- to 10-membered aromatic heterocycle, Z represents —O—, —N(R 7a )—, an optionally substituted 6- to 10-membered divalent aromatic ring group, an optionally substituted 5- to 10-membered divalent aromatic heterocyclic group, an optionally substituted 4- to 10-membered divalent non-aryl heterocyclic group, and R 1 , R 2a , R 2b , R 3 , R 4 , and R 5 are as described in the specification, or a pharmaceutically acceptable salt thereof.
1 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is
2-[(1′S,3′R)-3′-fluoro-5′-{1-[1-(oxetan-3-yl)azetidin-3-yl]-1H-pyrazol-4-yl}-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-inden]-1-yl]-N-[(5-fluoropyridin-2-yl)methyl]-N-[3-(trifluoromethyl)oxetan-3-yl]acetamide.
2 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is
2-[(1′S,3′R)-3′-fluoro-5′-(1-methyl-1H-pyrazol-4-yl)-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-inden]-1-yl]-N-[(4-fluorophenyl)methyl]-N-[1-methyl-3-(trifluoromethyl)azetidin-3-yl]acetamide.
3 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is
2-[(1′S,3′R)-3′-fluoro-5′-(1-methyl-1H-pyrazol-4-yl)-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-inden]-1-yl]-N-[(5-fluoropyridin-2-yl)methyl]-N-[1-methyl-3-(trifluoromethyl)azetidin-3-yl]acetamide.
4 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is
2-{(1′S,3′R)-3′-fluoro-5′-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-inden]-1-yl}-N-[(5-fluoropyridin-2-yl)methyl]-N-[1-methyl-3-(trifluoromethyl)azetidin-3-yl]acetamide.
5 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is
2-[(1′S,3′R)-3′-fluoro-5′-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-2,5-dioxo-2′,3′-dihydrospiro[imidazolidine-4,1′-inden]-1-yl]-N-[(5-fluoropyridin-2-yl)methyl]-N-[1-methyl-3-(trifluoromethyl)azetidin-3-yl]acetamide.
6 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is
2-[(1′S,3′R)-5′-(1-ethyl-1H-pyrazol-4-yl)-3′-fluoro-2,5-dioxo-2′,3′-dihydrospiro [imidazolidine-4,1′-inden]-1-yl]-N-[(4-fluorophenyl)methyl]-N-[1-methyl-3-(trifluoromethyl)azetidin-3-yl]acetamide.
7 . A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 .
8 . A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 , comprised as a combination with an additional drug, wherein the additional drug is at least one selected from the group consisting of a hormonal therapy agent, a chemotherapeutic agent, an immunotherapeutic agent, and an agent inhibiting a cell growth factor and a receptor action thereof.